Provided by Tiger Fintech (Singapore) Pte. Ltd.

Foghorn Therapeutics Inc.

4.43
-0.0500-1.12%
Post-market: 4.430.00000.00%17:45 EDT
Volume:44.98K
Turnover:202.20K
Market Cap:246.28M
PE:-2.42
High:4.73
Open:4.57
Low:4.39
Close:4.48
Loading ...

Foghorn Therapeutics initiated with a Buy at B. Riley

TIPRANKS
·
30 Jan

Optimistic Outlook on Foghorn Therapeutics Amid Market Opportunities and Strategic Developments

TIPRANKS
·
30 Jan

BRIEF-Foghorn Therapeutics Inc. Files For Mixed Shelf Of Up To $300 Million - SEC Filing

Reuters
·
25 Jan

Foghorn Therapeutics Files $300 Million Mixed Securities Shelf

MT Newswires Live
·
25 Jan

Foghorn Therapeutics files $300M mixed securities shelf

TIPRANKS
·
25 Jan

Foghorn Therapeutics Outlines Year Ahead for Oncology Drug Candidates

MT Newswires Live
·
13 Jan

Foghorn Therapeutics Inc.: Strong Balance Sheet With Cash, Cash Equivalents, and Marketable Securities of $243.8 Mln Provides Cash Runway Into 2027

THOMSON REUTERS
·
13 Jan

Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025

THOMSON REUTERS
·
13 Jan

Foghorn Therapeutics (FHTX) Upgraded to Strong Buy: Here's What You Should Know

Zacks
·
10 Jan

More Unpleasant Surprises Could Be In Store For Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares After Tumbling 41%

Simply Wall St.
·
01 Jan

Foghorn Therapeutics Board Member Resignation Announced

TIPRANKS
·
30 Dec 2024

Foghorn Therapeutics price target lowered to $13 from $20 at H.C. Wainwright

TipRanks
·
18 Dec 2024

Foghorn Therapeutics price target lowered to $4 from $9 at Morgan Stanley

TIPRANKS
·
18 Dec 2024

Foghorn Therapeutics Inc. : H.c. Wainwright Cuts Target Price to $13 From $20

THOMSON REUTERS
·
17 Dec 2024

Foghorn Therapeutics: Hold Rating Amid Strategic Pivot and Uncertainty in Drug Development

TIPRANKS
·
17 Dec 2024

Foghorn Therapeutics Shares Down 10.9% After Co Halts Independent Development of Cancer Treatment

THOMSON REUTERS
·
16 Dec 2024